Cargando…
Antithrombotic Therapy in Cardiac Embolism
Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd.
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994115/ https://www.ncbi.nlm.nih.gov/pubmed/21804782 http://dx.doi.org/10.2174/157340310791658749 |
_version_ | 1782192886500032512 |
---|---|
author | Cervera, Álvaro Chamorro, Ángel |
author_facet | Cervera, Álvaro Chamorro, Ángel |
author_sort | Cervera, Álvaro |
collection | PubMed |
description | Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is safe even in moderate acute strokes. The efficacy of early anticoagulation after cardioembolic stroke in relation to outcome has not been assessed adequately, but there is evidence from animal models and clinical studies that anticoagulation with unfractionated heparin is associated with a better outcome mediated in part by its anti-inflammatory properties. |
format | Text |
id | pubmed-2994115 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Bentham Science Publishers Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-29941152011-08-01 Antithrombotic Therapy in Cardiac Embolism Cervera, Álvaro Chamorro, Ángel Curr Cardiol Rev Article Anticoagulation is indicated in most cardioembolic ischemic strokes for secondary prevention. In many cardiac conditions, anticoagulation is also indication for primary stroke prevention, mainly when associated to vascular risk factors. Anticoagulation should be started as soon as possible, as it is safe even in moderate acute strokes. The efficacy of early anticoagulation after cardioembolic stroke in relation to outcome has not been assessed adequately, but there is evidence from animal models and clinical studies that anticoagulation with unfractionated heparin is associated with a better outcome mediated in part by its anti-inflammatory properties. Bentham Science Publishers Ltd. 2010-08 /pmc/articles/PMC2994115/ /pubmed/21804782 http://dx.doi.org/10.2174/157340310791658749 Text en © 2010 Bentham Science Publishers Ltd. http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Cervera, Álvaro Chamorro, Ángel Antithrombotic Therapy in Cardiac Embolism |
title | Antithrombotic Therapy in Cardiac Embolism |
title_full | Antithrombotic Therapy in Cardiac Embolism |
title_fullStr | Antithrombotic Therapy in Cardiac Embolism |
title_full_unstemmed | Antithrombotic Therapy in Cardiac Embolism |
title_short | Antithrombotic Therapy in Cardiac Embolism |
title_sort | antithrombotic therapy in cardiac embolism |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994115/ https://www.ncbi.nlm.nih.gov/pubmed/21804782 http://dx.doi.org/10.2174/157340310791658749 |
work_keys_str_mv | AT cerveraalvaro antithrombotictherapyincardiacembolism AT chamorroangel antithrombotictherapyincardiacembolism |